At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
COEP COEPTIS THERAPEUTICS HOLDINGS INC
Market Closed 05-17 16:00:00 EDT
0.3501
-0.0052
-1.46%
盘后0.3326
-0.0175-5.00%
19:49 EDT
High0.3800
Low0.3501
Vol34.59K
Open0.3502
D1 Closing0.3553
Amplitude8.42%
Mkt Cap12.64M
Tradable Cap7.07M
Total Shares36.09M
T/O12.58K
T/O Rate0.17%
Tradable Shares20.21M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.